000 02248nam a22002537a 4500
003 OSt
005 20240305192632.0
008 230113b |||||||| |||| 00| 0 eng d
020 _a 978-1-4987-1896-7
040 _cDLC
041 _aEnglish
100 _aIan M. Anderson
_948013
222 _aCommon terms and phrases
_bacid action activity Acute adverse effects agonist alcohol antagonists antidepressants antipsychotics anxiety appear associated atypical autoreceptor behavioural benzodiazepines binding bipolar block brain CAMP causes cell changes channel Chapter choline clinical clinical trials Clomipramine clozapine cognitive compounds concentration controlled D₂ decrease dementia dependence depression developed disease disorder distribution dopamine dose drug efficacy elimination enzyme evidence factors Figure formed function GABA given glutamate groups half-life important improvement increase Indications inhibition inhibitors interactions leads less levels lithium measures mechanism medication metabolised mood neuron neurotransmitter occur opioid outcome panic particular pathways patients Phase placebo plasma possible postsynaptic potential practice presynaptic properties protein Psychiatry psychopharmacology randomised receptor reduce release reported response reuptake risk role schizophrenia selective severe side effects SSRIs stimulation studies symptoms Table TCAs terminal therapeutic therapy tion treated treatment trials usually withdrawal
245 _aFundamentals of Clinical Psychopharmacology
250 _a4th, edition illustrated, reprint, revised
260 _aLondon:
_bCRC Press,
_cc2016
300 _a272 Pages
520 _aIn the rapidly changing field of pharmacology, it is essential that all those involved in the prescribing or administering of medication to people with mental disorders keep up to date with the latest developments. This book is based on the highly successful course for trainee psychiatrists held twice yearly in Great Britain. Leading psychiatrists
600 _xMedical / Psychiatry / General
_926946
600 _xMedical / Pharmacy
_927229
600 _xMedical  › Psychiatry  › General
_947581
700 _a Ian C. Reid
_948014
942 _2ddc
_cEB
999 _c9711
_d9711